Stromal cell derived factor-1 (sdf-1) targeting reperfusion reduces myocardial infarction in isolated rat hearts

Cardiovascular Therapeutics

Volumn 30, Issue 5, 2012, Pages 264-272

  Jang, Young Ho ^a   Kim, June Hong ^a   Ban, Changill ^b   Ahn, Kyohan ^b   Cheong, Jae Hun ^a   Kim, Hyung Hoi ^c   Kim, Jung Soo ^a   Park, Yong Hyun ^a   Kim, Jun ^a   Chun, Kook Jin ^a   Lee, Gyeong Ho ^d   Kim, Miju ^c   Kim, Cheolmin ^c   Xu, Zhelong ^e  

^a Pusan National University   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Keimyung University   (South Korea)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemia reperfusion injury; Ischemic heart disease; Myocardial infarction; SDF 1

Indexed keywords

STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR RISK; CORONARY ARTERY LIGATION; DIAGNOSTIC TEST ACCURACY STUDY; DOSE RESPONSE; HEART INFARCTION; HEART INFARCTION SIZE; ISCHEMIC POSTCONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; REVIEW; SPRAGUE DAWLEY RAT;

ANIMALS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CHEMOKINE CXCL12; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART; HEART FUNCTION TESTS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 84866029591     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00301.x     Document Type: Review

References (29)

1. Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-1135.
2. Burt R, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008;299:925-936.
3. Hausenloy D, Yellon D. Time to take myocardial reperfusion injury seriously. N Engl J Med 2008;359:518-520.
4. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
5. Askari A, Unzek S, Popovic Z, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003;362:697-703.
6. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004;110:3300-3305.
7. Ripa R, Wang Y, Goetze J, et al. Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease-indicators of myocardial ischemic burden?Int J Cardiol 2007;120:181-187.
8. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008;77:134-142.
9. Tang J, Wang J, Yang J, Kong X. Adenovirus-mediated stromal cell-derived- factor-1alpha gene transfer induces cardiac preservation after infarction via angiogenesis of CD133+ stem cells and anti-apoptosis. Interact Cardiovasc Thorac Surg 2008;7:767-770.
10. Tang J, Wang J, Yang J, et al. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur J Cardiothorac Surg 2009;36:644-650.
11. Hu X, Dai S, Wu W, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: Role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007;116:654-663.
12. Lin J, Chen Y, Chiang H, Hiang HS, Ma MC. Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: Role of erythropoietin on progenitor cell mobilization. J Physiol 2008;586:5757-5769.
13. Saxena A, Fish J, White M, et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008;117:2224-2231.
14. Oganesyan N, Kim S, Kim R. On-column protein refolding for crystallization. J Struct Funct Genomics 2005;6:177-182.
15. Ryu E, Kim T, Kwon T, et al. Crystal structure of recombinant human stromal cell-derived factor-1alpha. Proteins 2007;67:1193-1197.
16. Jang Y, Xi J, Wang H, et al. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008;108:243-250.
17. Song D, Jang Y, Kim J, Chun KJ, Lee D, Xu Z. Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K(ATP) channel activation in isolated rat hearts. J Korean Med Sci 2010;25:380-386.
18. Kamota T, Li T, Morikage N, et al. Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol 2009;53:1814-1822.
19. Penn M. Importance of the SDF-1: CXCR4 axis in myocardial repair. Circ Res 2009;104:1133-1135.
20. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc Res 2004;63:305-312.
21. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: Role of ERK1/2. Am J Physiol Heart Circ Physiol 2005;289:H1618-H1626.
22. Misra P, Lebeche D, Ly H, et al. Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J Nucl Med 2008;49:963-969.
23. Wang Y, Johnsen H, Mortensen S, et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 2006;92:768-774.
24. LaRocca TJ, Schwarzkopf M, Altman P, et al. β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol 2010;56:548-559.
25. Ibanez B, Prat-González S, Speidl W, et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: Analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 2007;115:2909-2916.
26. Segers V, Tokunou T, Higgins L, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007;116:1683-1692.
27. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008;117:1037-1044.
28. Ross A, Gibbons R, Stone G, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.
29. Stone G, Martin J, de Boer M, et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366-375.